Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Intas Pharmaceuticals Limited
WARNING LETTER
•Intas Pharmaceuticals Limited•December 2, 2022

Intas Pharmaceuticals Limited – FDA Warning Letter, Dec 2, 2022

Record Details

The FDA issued a Warning Letter to Intas Pharmaceuticals Limited following a November 22 to December 02, 2022, inspection of their drug manufacturing facility in Sanand, India. The inspection revealed significant violations of current Good Manufacturing Practice (CGMP) regulations, rendering their drug products adulterated.

Key violations include the quality control unit's failure to ensure CGMP compliance and data reliability. Specific issues involved inadequate oversight of original CGMP documents (e.g., torn and discarded records found in scrap areas), deficient controls over computerized systems (e.g., manual alterations in electronic batch records, unapproved chromatogram reprocessing, unutilized electronic data storage for instruments), and insufficient laboratory investigations (e.g., invalidated OOS results without justification, high number of aborted chromatographic sequences without systemic CAPA).

Additionally, the firm failed to ensure complete laboratory records, with inaccurate environmental monitoring data and missing raw data. They also lacked appropriate procedures for chromatographic peak integration and failed to adequately validate the manufacturing process for certain drug products, omitting a failed process validation batch from reports. Furthermore, the firm did not establish the accuracy, sensitivity, specificity, and reproducibility of test methods for raw materials.

The FDA deemed the company's responses inadequate, citing a lack of comprehensive evaluation of deficiencies and insufficient management oversight. The letter requires detailed corrective actions, including comprehensive investigations into data inaccuracies, a risk assessment, and a global CAPA plan. Repeat observations from previous inspections indicate inadequate executive management

Company
Intas Pharmaceuticals Limited
Inspection date
December 2, 2022
Product type
Drugs
Office
Center for Drug Evaluation and Research
People
  • Francis Godwin (Director)
  • Erika V. Butler (Compliance Officer / Investigator)
View Company Profile

ID · 69e72c80-0677-41df-92b7-50c9a9d7402e

Violation Codes4
21 U.S.C. 351(a)(2)(B)21 CFR 21021 CFR 211FD&C Act 801(a)(3)

Full citation text and observation details available on the Dashboard.

Other documents for Intas Pharmaceuticals Limited
  • WARNING_LETTER - 2023-05-12May 12, 2023
  • 483 - 2022-12-02December 2, 2022
  • 483 - 2020-02-28February 28, 2020
  • 483 - 2019-05-28May 28, 2019

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Intas Pharmaceuticals Limited
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.